Unichem outlines manufacturing plan for generic Hyzaar

By Gareth Macdonald contact

- Last updated on GMT

iStock/AVNphotolab
iStock/AVNphotolab

Related tags: Active pharmaceutical ingredients, Hypertension

Unichem Laboratories Limited has confirmed it will make its generic version of Hyzaar for the US market at three plants in India.

The Mumbai-headquartered firm said it will make the active pharmaceutical ingredients (API) - losartan potassium and hydrochlorothiazide – at its facilities in Pithampur, Madhya Pradesh and Roha, Maharashtra.

Unichem also confirmed in a Bombay Stock Exchange (BSE) filing​ that it will make the finished formulation of the drug – which is a version of Merck & Co’s blood pressure pill - at its manufacturing facility in Ghaziabad, Uttar Pradesh.

The US Food and Drug Administration (FDA) approved Unichem’s version of the drug earlier this week.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Related suppliers

Follow us

Products

View more

Webinars